In the 1990s, there was an acceleration in gene therapy trials, marked by the first authorized attempt to use retroviral vectors expressing adenosine deaminase (ADA) in a gene therapy trial for treating ADA deficiency, which causes severe combined immunodeficiency [11]. Here, ADA is linked to immune system disorder.